| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sildenafil | CTRPv2 | pan-cancer | AAC | -0.041 | 0.3 |
| mRNA | MI-2 | CTRPv2 | pan-cancer | AAC | -0.056 | 0.3 |
| mRNA | L-685458 | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | Tamoxifen | CTRPv2 | pan-cancer | AAC | -0.04 | 0.3 |
| mRNA | BRD-K52037352 | CTRPv2 | pan-cancer | AAC | 0.043 | 0.3 |
| mRNA | Erlotinib | gCSI | pan-cancer | AAC | -0.058 | 0.3 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | FSC231 | CTRPv2 | pan-cancer | AAC | -0.074 | 0.3 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | 0.061 | 0.3 |
| mRNA | SB-743921 | CTRPv2 | pan-cancer | AAC | -0.034 | 0.3 |